A US vaccine advisory panel, led by Health Secretary Robert F. Kennedy Jr., has voted to eliminate a key recommendation that newborn babies receive the hepatitis B vaccine immediately after birth. The decision was made without any evidence of harm from the one-time dose or data showing benefits from delaying it.
Critics on the committee, including some members who voted against the change, argue that this move will lead to more cases of hepatitis B infection in babies and increase the risk of chronic liver disease, liver cancer, and premature death. The committee's decision is also seen as undermining decades of public trust in a vaccine widely recognized for its life-saving benefits.
The recommendation was made after attempts to vaccinate only high-risk infants failed, leading to a significant spike in infected infants between 1979 and 1989. However, this universal recommendation has been in place since 1991, with the hepatitis B vaccine being administered at birth nearly eliminating post-birth infections.
Despite the lack of data supporting the change, the committee voted 8-3 to withdraw the long-standing universal recommendation and instead recommended a new approach where only babies born to mothers known to be infected with the virus or those born to untested mothers should receive the birth dose. Parents would then use "individual-based decision making" to decide if the vaccine is necessary for their child.
Experts are warning that this new approach creates an opportunity for newborns to contract the highly infectious virus from false-negative test results or other sources, putting thousands of lives at risk in the US alone. Only a small percentage of infected individuals are aware they carry the virus.
Critics, including medical experts and some members of the committee, have condemned the decision as "reckless" and "based on baseless skepticism." The move is seen as an attempt to undermine public confidence in vaccines and may lead to confusion among parents about how best to protect their newborns.
Critics on the committee, including some members who voted against the change, argue that this move will lead to more cases of hepatitis B infection in babies and increase the risk of chronic liver disease, liver cancer, and premature death. The committee's decision is also seen as undermining decades of public trust in a vaccine widely recognized for its life-saving benefits.
The recommendation was made after attempts to vaccinate only high-risk infants failed, leading to a significant spike in infected infants between 1979 and 1989. However, this universal recommendation has been in place since 1991, with the hepatitis B vaccine being administered at birth nearly eliminating post-birth infections.
Despite the lack of data supporting the change, the committee voted 8-3 to withdraw the long-standing universal recommendation and instead recommended a new approach where only babies born to mothers known to be infected with the virus or those born to untested mothers should receive the birth dose. Parents would then use "individual-based decision making" to decide if the vaccine is necessary for their child.
Experts are warning that this new approach creates an opportunity for newborns to contract the highly infectious virus from false-negative test results or other sources, putting thousands of lives at risk in the US alone. Only a small percentage of infected individuals are aware they carry the virus.
Critics, including medical experts and some members of the committee, have condemned the decision as "reckless" and "based on baseless skepticism." The move is seen as an attempt to undermine public confidence in vaccines and may lead to confusion among parents about how best to protect their newborns.